Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/14507
Title: | Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics |
Authors: | Chittasupho C. Siahaan T.J. Vines C.M. Berkland C. |
Keywords: | abatacept adalimumab autoantibody B7 antigen belatacept CD28 antigen cholinergic receptor corticosteroid derivative cytokine cytotoxic agent cytotoxic T lymphocyte antigen 4 dacetuzumab efalizumab etanercept galiximab immunoglobulin infliximab intercellular adhesion molecule 1 intercellular adhesion molecule 1 antibody ipilimumab lymphocyte function associated antigen 1 major histocompatibility antigen class 2 membrane protein methotrexate natalizumab programmed death 1 receptor rituximab thyrotropin receptor ticilimumab unindexed drug antigen presenting cell autoimmune disease autoimmunity B cell lymphoma brain infection brain ischemia cell adhesion cellular immunity chronic lymphatic leukemia Crohn disease cytokine production drug protein binding drug receptor binding drug targeting drug withdrawal human immunological synapse immunoregulation immunostimulation lymphocyte proliferation melanoma multiple myeloma multiple sclerosis nonhodgkin lymphoma nonhuman phase 1 clinical trial (topic) phase 2 clinical trial (topic) phase 3 clinical trial (topic) priority journal progressive multifocal leukoencephalopathy psoriasis review rheumatoid arthritis signal transduction T lymphocyte activation Animals Autoimmune Diseases Cell Adhesion Drug Delivery Systems Humans Immune Tolerance Immunological Synapses Inflammation Proteins Signal Transduction |
Issue Date: | 2011 |
Abstract: | Proteins participating in immunological signaling have emerged as important targets for controlling the immune response. A multitude of receptor-ligand pairs that regulate signaling pathways of the immune response have been identified. In the complex milieu of immune signaling, therapeutic agents targeting mediators of cellular signaling often either activate an inflammatory immune response or induce tolerance. This review is primarily focused on therapeutics that inhibit the inflammatory immune response by targeting membrane-bound proteins regulating costimulation or mediating immune-cell adhesion. Many of these signals participate in larger, organized structures such as the immunological synapse. Receptor clustering and arrangement into organized structures is also reviewed and emerging trends implicating a potential role for multivalent therapeutics is posited. © 2011 Future Science Ltd. |
URI: | https://ir.swu.ac.th/jspui/handle/123456789/14507 https://www.scopus.com/inward/record.uri?eid=2-s2.0-79961177838&doi=10.4155%2ftde.11.60&partnerID=40&md5=34201a5607326ab185a08e4094899c9d |
ISSN: | 20415990 |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.